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Abstract 
Background: Macrophages (Mφs) constitute a major component of the leukocyte infiltrate and perform distinct 
roles in different tumor microenvironments. This study aimed to characterize the distribution, composition and prog‑
nostic value of Mφs in hepatocellular carcinoma (HCC) and gastric cancer (GC).
Methods: Immunohistochemistry and immunofluorescence were used to identify Mφ subsets in HCC and GC tis‑
sues. Kaplan–Meier analysis and Cox regression models were applied to estimate the overall survival (OS) for HCC and 
GC patients.
Results: The results showed that the density of Mφs decreased in the intra‑tumor region (IT) of HCC, but remarkably 
increased in the IT of GC, as compared with their non‑tumor regions (NT). In HCC, most CD68+ Mφs were CD204+ 
and CD169+ cells in the NT region; however, there was a significant decrease in the percentage of CD169+ Mφ in the 
IT region. In contrast, CD68+ Mφs comprised a smaller percentage of CD204+ than the CD169+ subpopulation in the 
NT region, while more CD204+ but fewer CD169+ cells were present in the IT region of GC. The density of CD204+ 
Mφs correlated with poor prognosis in HCC, and CD169+ Mφs were associated with good survival in both HCC and 
GC. Moreover, the combination of low numbers of CD204+ and high numbers of CD169+ Mφs was associated with 
improved OS in both GC and HCC.
Conclusions: Mφs display tissue‑specific distributions and distinct composition patterns in HCC and GC tissues. Our 
results suggested that different types of tumors might use diverse strategies to reconstitute Mφ patterns to promote 
tumor progression.
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Background
Macrophages (Mφs) are essential components of the 
innate immune system and are widely distributed 
throughout the body [1]. High numbers of tumor-asso-
ciated Mφs are found in tumors and constitute a major 
component of the inflammatory infiltrate in virtu-
ally all malignancies [2, 3]. The variety of local tumor 
environmental conditions could shape the Mφ identity 
and Mφs have both pro- and anti-tumorigenic functions, 
thus making them an attractive target for novel anti-can-
cer therapies [4, 5].
Hepatocellular carcinoma (HCC) and gastric cancer 
(GC) are the most common malignancies and leading 
causes of cancer mortality worldwide [6]. The increasing 
incidence of HCC has been attributed to the dissemina-
tion of hepatitis B (HBV) and hepatitis C (HCV) virus 
infection; while Helicobacter pylori infection is the prin-
ciple risk factor for the development of the chronic gas-
tric inflammation that progresses to GC [7–9]. Despite 




*Correspondence:  fangyj@sysucc.org.cn; xujing@sysucc.org.cn 
†Jin‑Qing Li and Xing‑Juan Yu contributed equally to this work 
1 Collaborative Innovation Center of Cancer Medicine, State Key 
Laboratory of Oncology in South China, Sun Yat‑sen University Cancer 
Center, Guangzhou 510060, People’s Republic of China
Full list of author information is available at the end of the article
Page 2 of 11Li et al. J Transl Med  (2017) 15:37 
tissue-specific functions could also determine the source 
and function of Mφs [10–12]. In the gastrointestinal sys-
tem, Mφs are derived from circulating monocytes and 
function as sentinels of the immune system to avoid col-
lateral damage by secretion of the pro-inflammatory 
cytokines that are induced by bacterial products [13]. 
By contrast, in the liver, Mφs are predominantly self-
renewed from resident stem cells that originated from 
the fetal yolk-sack during homeostasis, but can also be 
recruited from blood monocytes after liver injury [14]. 
The distinct local environments and cell sources might 
contribute to the development of Mφs in these two types 
of tumor; however, presently there is a lack of human 
studies comparing the distribution, phenotype and clini-
cal relevance of Mφs in these tumors.
Diverse Mφ subpopulations can be distinguished based 
on the expression of several specific markers. CD68, a 
pan-Mφ marker, has been used widely to evaluate Mφ 
density in different types of tumors. Our and other groups 
have shown that a high density of CD68+ Mφs correlates 
with a negative outcome in HCC patients; however, con-
flicting data were produced in GC [15–18]. To potentially 
represent more selective Mφs, some other phenotypic 
markers of Mφs have been reported. Biomarkers such 
as CD163, CD204 which are considered to be associated 
with M2 activation state, have been found to correlate 
with negative outcomes in multiple tumor types [19–24]. 
CD204 is a phagocytic pattern-recognition receptor that 
is primarily expressed on myeloid lineage cells. The high 
density of CD204+ Mφs have been reported to be associ-
ated with poor outcomes in both GC and HCC patients 
[25, 26]. Mφ could also possess anti-tumor phenotypic 
state (M1), which were correlated with good prognosis 
in some tumors [27]. Our recent study demonstrated that 
CD169+ Mφs can dominate anti-tumor immunity and 
are correlated with improved prognosis in HCC patients 
[28]. However, there is a lack of studies examining the 
differences and similarities in the composition pattern of 
Mφs subtypes in different types of tumors.
In this study, we assessed the tissue-specific distribu-
tion and composition of different Mφ subpopulations in 
HCC and GC tissues, and investigated the prognostic sig-




Archived, formalin-fixed, paraffin-embedded (FFPE) tis-
sues from 188 HCC patients and 138 GC patients who 
had all undergone radical resection for tumors at the 
Sun Yat-Sen University Cancer Center between 2002 and 
2012 were enrolled in this study. Patients who exhibited 
signs of distant metastasis and had received anti-cancer 
therapies before surgery, or experienced concurrent 
autoimmune disease, were excluded. The diagnosis of 
HCC and GC in each patient was confirmed histopatho-
logically. The tumor stage was determined according to 
the tumor-node-metastasis (TNM) classification system 
of the International Union Against Cancer, 7th Edition. 
Data was censored at the last follow-up for surviving 
patients. Overall survival (OS) was defined as the interval 
between the time of surgery and either the last follow-up 
or death.
This study conformed strictly to the ethical guidelines 
of the Declaration of Helsinki and was approved by the 
Research Ethics Committee of Sun Yat-Sen University 
Cancer Center. Written informed consent was obtained 
from all patients before sample collection. All samples 
were coded and data was stored anonymously. The clin-
icopathological characteristics of the patients are sum-
marized in Table 1.
Immunohistochemistry (IHC) and immunofluorescence 
staining
IHC was performed using a two-step method (DakoCy-
tomation, Glostrup, Denmark) using protocols described 
in our previous studies [29, 30]. Sections of FFPE tissues 
were cut using a microtome, and then sequentially dried, 
dewaxed, and re-hydrated with xylene and a decreasing 
ethanol series. Endogenous peroxidase activity was then 
blocked with 0.3% H2O2 for 10 min. For antigen retrieval, 
sections were steamed in 10 mM citrate buffer (pH 6.0) for 
10 min. Glass slides were incubated overnight at 4 °C with 
anti-CD204 (Transgenic, Kumamoto, Japan), anti-CD169 
(R&D Systems, Minneapolis, MN, USA), or anti-CD68 
(DakoCytomation, Carpinteria, CA, USA) antibodies. 
Horseradish peroxidase-conjugated anti-rabbit and anti-
mouse antibodies from Dako EnVision systems (DakoCy-
tomation) were used as secondary detection reagents and 
the immunoreactivities were visualized using 3,3′-diamin-
obenzidine (DAB). All sections were lightly counterstained 
with Mayer’s Hematoxylin Solution (Sigma) and mounted 
using non-aqueous Permount™ mounting medium. Nega-
tive controls comprised slides for which the primary anti-
bodies were replaced by the same concentration of an 
irrelevant, isotype-matched antibody.
Double immunofluorescent staining was carried out 
as previously described [30]. Briefly, re-hydrated FFPE 
sections were incubated at 4  °C overnight with mouse 
anti-human CD68, rabbit anti-human CD204, or sheep 
anti-human CD169 antibodies. The sections were then 
incubated for 30 min at 37 °C with a mixture of primary-
antibody-matched fluorescently labeled secondary anti-
bodies (Invitrogen; Carlsbad, CA, USA). Nuclei were 
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counterstained using 4′,6-diamidino-2-phenylindole 
(DAPI).
Image quantification
To quantify CD204+ and CD169+ cell density, the Vec-
tra-Inform image analysis system (Perkin-Elmer/Applied 
Biosystems, Foster City, CA, USA) was used, as described 
in a previous study [28, 30]. Target signals were quanti-
fied in selected tissues and cellular compartments of 
interest. The percentage of each immune cell subset was 
calculated by dividing the absolute number of each cell 
subset by area of the tissue surface.
Quantification methods for immunofluorescence were 
performed as previously described [30]. Immunofluores-
cence images were captured using a confocal microscope 
(Olympus, Essex, UK) and analyzed using FV10-ASW 
Viewer (Olympus, Essex, UK). The number of single-pos-
itive or double-positive cells in each of five representa-
tive fields at 400× magnification were counted. From 
these numbers, the proportions of CD204+ or CD169+ 
cells in CD68+ Mφs were calculated as: (number of 
CD204+CD68+ cells)/(number of CD68+ Mφs), or (num-
ber of CD169+CD68+ cells)/(number of CD68+ Mφs).
Statistical analyses
OS curves were obtained using the Kaplan–Meier 
method, and compared using the log-rank test for each 
prognostic variable. Variables with effects on survival in 
univariate analysis were included in a multivariate Cox 
proportional hazard regression model, which was used to 
estimate the adjusted hazard ratio (HR) and 95% confi-
dence interval (CI), and to identify independent prognos-
tic factors. Subgroups of each immunostaining parameter 
were divided by the median values. Associations between 
immunostaining parameters and clinicopathological fea-
tures were evaluated using the χ2 test or Fisher’s exact 
test, as appropriate. A threshold of P < 0.05 denoted sta-
tistical significance. SPSS 20.0 (IBM) was used for the 
statistical analyses.
Results
Distribution of Mφs in HCC and GC
To evaluate the in situ distribution of different Mφ sub-
populations, we used immunostaining to detect CD68+ 
Mφs, CD204+ Mφs, and CD169+ Mφs in the non-tumor 
(NT) and intra-tumor (IT) areas of HCC and GC. Clear 
and distinguishable staining was observed for all the phe-
notypic markers. In HCC, Mφs were evenly distributed 
in the parenchyma of both the NT and IT regions. In GC, 
Mφs were gathered in the stromal area surrounded the 
glandular tubes of gut tissue, but were scattered distrib-
uted in the tumor nest (Fig. 1a).
We compared the density of Mφs in the NT and IT 
regions of HCC and GC. Statistics showed that the num-
bers of CD68+ Mφs were high in the NT of HCC, but 
were relatively low in the NT of GC tissues, with mean 
(±SEM) densities of 859 ± 19, and 378 ± 28 in HCC and 
GC, respectively (P < 0.001; Fig. 1b). However, the density 
decreased in the IT of HCC (660 ± 28), while it remarkably 
increased in the IT of GC (604 ± 29). We also compared 
the distribution of different Mφ subpopulations. In HCC, 
the densities of both CD204+ Mφs (826 ± 77 and 526 ± 23 
in NT and IT, respectively; P < 0.001; Fig. 1c) and CD169+ 
Mφs (760 ± 22 and 187 ± 16 in NT and IT, respectively; 
P  <  0.001; Fig.  1d) also decreased in the IT compared 
with the NT region. In GC, only a few CD204+ Mφs were 
found in the NT, but they were significantly enriched in 
the IT (31 ±  5 and 411 ±  27 in the NT and IT, respec-
tively; P  <  0.001; Fig.  1c). Moreover, CD169+ Mφs could 
be detected in the NT region and were also increased in 
the IT of GC (242 ± 20 and 514 ± 37 in the NT and IT, 
respectively; P < 0.001; Fig. 1d). In addition, the ratios of 
CD204+/CD169+ Mφs were significantly increased in 
IT as compared with NT regions of HCC but not in GC 
(1.2 ± 0.05 and 14.1 ± 1.9 in the NT and IT, respectively; 
P < 0.01; Fig. 1e). Taken together, the distribution of Mφs 
in the NT and IT areas differed in HCC and GC.
Table 1 Clinicopathological characteristics of the patients




No. of patients 188
Age (median; range), years 50; 13–76
Gender (male/female) 159/29 (84.6/15.4)
HBV infection (no/yes) 19/169 (10.1/89.9)
Alpha‑fetoprotein, ng/mL (≤2 
5/>25)
74/114 (39.4/60.6)
Child–Pugh class (A/B) 175/13 (93.1/6.9)
Tumor number (single/multiple) 144/44 (76.6/23.4)
Tumor size, cm (≤5/>5) 80/108 (42.6/57.4)
Vascular invasion (absent/present) 177/11 (94.1/5.9)
TNM stage (I/II/III) 130/16/39 (69.1/10.1/20.8)
Histological grade (I/II/III/other) 125/63 (66.5/33.5)
GC patients
No. of patients 138
Age (median; range), years 69; 28–78
Gender (male/female) 100/38 (72.5/27.5)
Tumor size, cm (≤4/>4) 46/92 (33.3/66.7)
Tumor depth (pT1/pT2/pT3/pT4) 3/10/34/91 (2.2/7.2/24.7/65.9)
Lymph node metastasis (pN0/pN1/
pN2/pN3)
29/31/27/51 (21.0/22.5/19.5/37.0)
TNM stage (IA/IB/II/IIIA/IIIB/IIIC) 3/6/5/25/32/32/35 (2.2/4.3/3.6/18.1
/23.2/23.2/25.4)
Histological grade (I/II/III/other) 3/32/90/11 (2.2/23.2/65.2/8.0)
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Composition patterns of Mφs in HCC and GC
CD68 is always used as a pan-Mφ marker, while CD204 
and CD169 might represent different Mφ subpopulations 
with pro- or anti-tumor functions during tumor progres-
sion. Multiple immunofluorescence staining and confocal 
analyses confirmed that most CD204+ and CD169+ cells 
are CD68+ Mφs in both the NT and IT areas of HCC and 
GC (Fig. 2a; Additional file 1: Figures S1 and S2).
We then examined the proportion of each Mφ subpop-
ulation within CD68+ Mφs in HCC and GC. As shown in 
Fig. 2b, most CD68+ Mφs are CD204+ (92.8 ± 1.0%) and 
CD169+ (88.4 ± 3.2%) cells in the NT area of HCC; how-
ever, the phenotype changed in the IT area, as shown by 
a significant decrease in the percentage of CD169+ Mφs 
(P = 0.004; Fig. 2b). Moreover, the CD169+ (46.3 ± 8.0%) 




































































































Fig. 1 Mφs distributions in the non‑tumor (NT) and intra‑tumor (IT) regions of hepatocellular carcinoma (HCC) and gastric cancer (GC). a Repre‑
sentative immunohistochemistry images of CD68+ Mφs, CD204+ Mφs, and CD169+ Mφs in human HCC and GC tissues. Scale bar, 100 μm. b–d The 
numbers of CD68+ Mφs (b), CD204+ Mφs (c), CD169+ Mφs (d) and CD204+/CD169+ Mφs ratios (e) in the NT and IT regions of human HCC and GC 
tissues. Cell numbers were calculated as the cell count per ×400 field. Data are expressed as mean ± SEM. *P < 0.05; **P < 0.01
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CD204+ (82.3 ± 4.1%; P < 0.001; Fig. 2b) subpopulation 
within total CD68+ Mφs in the IT region of HCC.
The composition of Mφs displayed a different pattern 
in GC, in that CD68+ Mφs comprised fewer CD204+ 
cell (15.7 ± 4.4%) than CD169+ cell (60.9 ± 4.3%) in the 
NT region (P < 0.001; Fig. 2c). In contrast, more CD204+ 
(44.3  ±  6.1%) but fewer CD169+ (30.4  ±  8.5%) cells 
were found in CD68+ Mφs in the IT region. Notably, 
the CD169+ subpopulation of Mφs was also significantly 
decreased in the IT compared with the NT region of GC 
(P = 0.008; Fig. 2c).
Prognostic roles of CD204+ and CD169+ Mφ in HCC and GC
The relationship between the densities of CD204+/
CD169+ Mφs and patient survival was further investi-
gated. Patients were divided into two groups, based on 
the median value of CD204+ or CD169+ Mφ density in 





































































































Fig. 2 Composition patterns of Mφs subpopulations in CD68+ Mφs of HCC and GC intra‑tumor tissues. a Paraffin‑embedded tissue sections (n = 5) 
were subjected to three‑color immunofluorescence for CD204 (red) or CD169 (red) with CD68 (green) and DAPI counterstaining (blue) in the intra‑
tumor regions of HCC and GC. b–c Percentage of CD204+ Mφs and CD169+ Mφs subpopulations in CD68+ Mφs of HCC (b) and GC (c). Data are 
expressed as mean ± SEM. *P < 0.05; **P < 0.01
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CD204+ and CD169+ Mφ, respectively) and GC (median 
density, 352 and 452 for CD204+ and CD169+ Mφ, 
respectively). Kaplan–Meier survival analysis revealed a 
negative correlation between the density of CD204+ Mφs 
and the OS of HCC patients (P =  0.004; Fig.  3a); how-
ever, no significant association was found for GC patients 
(P = 0.899; Fig. 3a). In contrast, a high density of intra-
tumor CD169+ Mφs predicted favorable survival in both 
HCC (P  =  0.01) and GC (P  =  0.027; Fig.  3b) patients 
(Additional files 2, 3).
To further assess whether CD204+ or CD169+ Mφ den-
sity could be used as an independent predictor of OS, we 
performed multivariate Cox proportional hazards analysis. 
As shown in Table  2, the CD169+ Mφ density was asso-
ciated with a decreased risk of death in HCC (HR 0.561, 
95% CI 0.358–0.878, P = 0.011) and GC (HR 0.569, 95% CI 
0.343–0.943, P = 0.029) patients. By contrast, the CD204+ 
Mφ density was associated with an increased risk of death 
in HCC (HR 1.922, 95% CI 1.217–3.034, P =  0.005), but 
no significant association was found for GC patients (HR 
1.033, 95% CI 0.625–1.709, P = 0.899). Clinicopathologi-
cal variables that were shown to be significant in the uni-
variate analysis were used as covariates in the multivariate 
analysis. We found that the CD169+ Mφ density could act 
as an independent prognostic factor for OS in both HCC 
(HR 0.436, 95% CI 0.270–0.703, P = 0.001) and GC (HR 
0.587, 95% CI 0.354–0.974, P = 0.039) patients.
We also tested the association of CD204+/CD169+ 
Mφ density with CD8+ T cell infiltration. As shown in 
Fig.  4, the density of CD169+ Mφ was positively cor-
related with CD8+ T cells infiltration in both HCC and 
GC (P < 0.0001), indicating the anti-tumor functions of 
these Mφs in both tumors. However, no association was 
found for CD204+ Mφ in either HCC or GC (P > 0.05). 
The associations between the CD204+/CD169+ Mφ 
density and clinicopathological variables have also been 
analyzed. The density of CD204+ cells was significantly 
correlated with tumor number, tumor size, TNM stage 
and histological grade (P = 0.006, P = 0.004, P = 0.004, 
and P  =  0.002, respectively; Table  3) in HCC patients. 
No significant correlations were found between CD169+ 
cells density and clinicopathological variables in either 
HCC or GC.  
Prognostic power of the Mφ index in HCC and GC
Our findings indicated that the density of CD204+ and 
CD169+ Mφs represented a valuable independent factor 
to predict the prognosis of HCC. Therefore, we analyzed 
whether the combination of intra-tumor CD204+ and 
CD169+ Mφs (namely, the Mφ index) could represent a 
more powerful criterion for predicting patient prognoses.
In HCC, patients in the CD204low and CD169high group 
exhibited the best OS (5-year OS rate: 90.3%) compared 
with those in the CD204low and CD169low group (5-year 
OS rate: 64.2%, P  =  0.019), CD204high and CD169high 
group (5-year OS rate: 63.0%, P =  0.01) and CD204high 
and CD169low group (5-year OS rate: 38.9%, P < 0.0001; 
Fig.  3c). A similar trend was found in GC patients, but 
did not reach statistical significance. In addition, we also 
analyzed the prognostic value of CD204+/CD169+ Mφs 
ratio, and found high CD204+/CD169+ Mφs ratio was 
correlated with poor survival in HCC patients (P < 0.001 
Fig. 3d). In the multivariate Cox analysis, the Mφ index in 
HCC was also associated with OS in HCC, but not in GC 
(Additional file 1: Table S1).
Discussion
Mφs form a major component of the inflammatory infil-
trate in tumors, where they exhibit distinct phenotypes 
and diverse functions. In the present study, we investi-
gated the distribution and composition of Mφ subpopu-
lations in the NT and IT regions HCC and GC. Using 
CD204 and CD169 as subpopulation markers for Mφs, 
we found that most CD68+ Mφs were CD204+ and 
CD169+ cells in the NT region of HCC; however, the 
percentage of CD169+ Mφs deceased in the IT region. In 
contrast, CD68+ Mφs comprised a lower percentage of 
CD204+ than CD169+ subpopulations in the NT region, 
while more CD204+ but fewer CD169+ cells were in the 
IT region of GC. Moreover, the density of CD204+ Mφs 
was correlated with poor prognosis in HCC; however 
CD169+ Mφs are associated good survival in both HCC 
and GC.
In previous studies, various subpopulations of tumor-
associated Mφs were identified; however, conflicting 
prognostic data was reported [31]. CD68, a glycopro-
tein predominantly resident in intracellular granules, is a 
fairly specific marker for pan-Mφs. In HCC, we and other 
groups have demonstrated that the number of CD68+ 
Mφs in tumor o was negatively correlated with patient 
prognosis [15, 16]. However, the data for GC is conflict-
ing. For example, in some studies, CD68+ Mφs were cor-
related negatively with patient prognosis [32]; whereas, 
we and other groups have shown that GC patients with 
a high tumor-associated macrophage (TAM) count had 
better outcomes than those with a low TAM count [17, 
33]. The discrepancies are probably a consequence of dif-
ferences in the number, stage and size of tumors. In addi-
tion to these markers, there are also other phenotypes of 
Mφs, such as CD163+ and CD11c+ Mφs that exist in the 
different regions of tumors, which deserve further inves-
tigation [34, 35].
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Fig. 3 Cumulative overall survival curves of CD204+ Mφs and CD169+ Mφs for HCC and GC patients. Overall survival was estimated using the 
Kaplan–Meier method and compared using the log‑rank test for CD204+ Mφs (a), CD169+ Mφs (b), the Mφ index (c) and Mφ ratio (d) in HCC and 
GC patients. *P < 0.05; **P < 0.01
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In addition to potentially representing a Mφ biomarker, 
CD204, a cell-surface glycoprotein that belongs to the 
scavenger receptors that has a pro-tumoral function dur-
ing tumor progression [36], is associated with activation 
of Mφs toward an alternative or tumor-promoting and 
immunosuppressive phenotype. Accordingly, significant 
correlations between CD204 and negative outcomes 
have been reported across multiple tumor types [22–24]. 
CD169, also known as Siglec-1, belongs to the sialic-acid-
binding immunoglobulin-like lectin family, which 
includes molecules that can mediate cell–cell interactions 
via glycan recognition [37]. The expression and function 
of CD169 on TAMs are poorly understood. Our recent 
study revealed the anti-tumor function of CD169+ Mφs 
in HCC [28]. In the present study, we confirmed the posi-
tive prognostic role of CD169+ Mφs in HCC. Moreover, 
we found that the number of CD169+ Mφs also corre-
lated with good prognosis in GC patients. The function 
of CD169+ Mφs during GC progression deserves further 
investigation. Taken together, our results showed that the 
CD204+ and CD169+ Mφ subpopulations have diverse 
prognostic values during tumor progression.
Recent studies in mouse models revealed that Mφs can 
be generated from distinct sources in different organs, 
and the local environments might influence the function 
of Mφs [38, 39]. In this study, we found distinct com-
position patterns of these Mφ subpopulations within 
the NT and IT regions of HCC and GC, suggesting that 
environmental tissue factors in the gut and liver might 
contribute to the distinct developments of Mφs. We 
further found that the CD169+ Mφs density were cor-
related with more CD8+ T cells infiltration and good 
Table 2 Univariate and multivariate analyses of variables associated with overall survival
Cox proportional hazards regression model; variables that were associated with overall survival in the univariate analysis were adopted as covariates in the 
multivariate analysis and were entered into the equation using the forward likelihood ratio method
HCC hepatocellular carcinoma, GC gastric cancer, HBV hepatitis B virus, TNM tumor-lymph node-metastasis, CI confidence interval, NA not applicable, IT intra-tumor
a Italic values indicate significance of p value (p < 0.05)
Variables Univariate Multivariate
HR 95% CI Pa HR 95% CI Pa
HCC patients
 Gender (male/female) 1.333 0.747–2.377 0.331
 HBV infection (no/yes) 0.863 0.431–1.729 0.678
 Alpha‑fetoprotein, ng/mL (≤25/>25) 1.023 1.003–1.043 0.027 NA
 Child–Pugh class (A/B) 1.626 0.782–3.378 0.193
 Histological grage (I/II/III/other) 1.42 0.901–2.237 0.131
 Tumor number (single/multiple) 3.178 2.008–5.031 < 0.0001 NA
 Tumor size, cm (≤5/>5) 1.838 1.154–2.927 0.01 1.614 0.997–2.613 0.051
 Vascular invasion (absent/present) 3.832 1.825–8.046 < 0.0001 2.667 1.208–5.888 0.015
 TNM stage (I vs. II + III) 3.383 2.164–5.289 < 0.0001 2.838 1.765–4.564 0.0002
 CD204+
IT
 cells (low/high) 1.922 1.217–3.034 0.005 2.125 1.298–3.478 0.003
 CD169+
IT
 cells (low/high) 0.561 0.358–0.878 0.011 0.436 0.270–0.703 0.001
GC patients
 Gender (male/female) 1.189 0.702–2.013 0.52
 Tumor size, cm (≤4/>4) 1.655 0.951–2.881 0.075
 Tumor depth (pT1 + pT2 + pT3/pT4) 1.251 0.744–2.105 0.398
 Lymph node metastasis (pN0 + pN1/pN2 + pN3) 1.999 1.192–3.353 0.009 2.012 1.178–3.437 0.011
 TNM stage (I + II vs. III + IV) 2.031 1.103–3.738 0.023 NA
 Histological grage (I/II/III/other) 1.18 0.772–1.804 0.445
 CD204+
IT
 cells (low/high) 1.033 0.625–1.709 0.899
 CD169+
IT
 cells (low/high) 0.569 0.343–0.943 0.029 0.587 0.354–0.974 0.039
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prognosis in both HCC and GC, indicating the anti-
tumor functions of these Mφs in both tumors. These 
data suggested a similarity function but distribution dif-
ferences for Mφ subpopulations in different tumors. The 
underlying mechanisms that regulate the infiltration and 
development of Mφ subpopulations, such as their epige-
netic and transcriptional features which might be influ-
enced by local environmental factors, deserve further 
investigations.
Based on the data that most cancers are populated by 
M2  Mφ, preclinical and clinical studies in several solid 
tumor types are designed using CSF-1R inhibitors or 
blocking monoclonal antibodies to reduce the presence 
of TAM [4, 40, 41]. However, due to the plasticity of Mφ, 
modulating M2 to M1 Mφs that could stimulate Th1-type 
cytotoxic T cells and other effector cells are emerged as 
an important strategy for immunotherapy of cancer [42]. 
Considering the importance of the protective function 
and prognostic role of CD169+ Mφ in both HCC and 
GC, it may be worth investigating whether the selective 
overexpression of CD169 might represent a novel thera-
peutic approach to reprogram the anti-tumor activities of 
Mφ.
Conclusions
Our study demonstrated that CD204+ and CD169+ 
Mφ subpopulations display tissue-specific distributions 
and distinct composition patterns in different tissue 
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Fig. 4 The density of CD169+ Mφs was positively associated with CD8+ T cells in both HCC and GC tissues. Immunohistochemical quantification 
showing the associations between the densities of CD169+ Mφs (a) or CD204+ Mφs (b) and those of CD8+ T cells in the intra‑tumor regions of HCC 
and GC tissues. Correlations were performed by Spearman’s rank correlation coefficient test
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micro-localizations, and have diverse prognostic values 
during tumor progression in HCC and GC. The results 
could help to reveal the possible therapeutic implications 
of Mφs and how to restore the anti-tumor properties of 
Mφs for immunotherapies.
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Table 3 Association of Mφ with patients’ clinical characteristics
HCC hepatocellular carcinoma, GC gastric cancer, HBV hepatitis B virus, TNM tumor-lymph node-metastasis
a Data were missing for these variables in some patients: CD204+ Mφs, n = 183 and CD169+ Mφs, n = 188 in HCC; CD204+ Mφs, n = 131 and CD169+ Mφs, n = 132 in 
HCC
b Italic values indicate significance of p value (p < 0.05)
Characteristics CD204+ Mφsa Pb CD169+ Mφsa Pb
Low High Low High
HCC patients
 Gender (male/female) 73/19 81/10 0.104 75/19 81/10 0.105
 HBV infection (no/yes) 7/85 11/80 0.333 8/86 11/83 0.629
 Alpha‑fetoprotein, ng/mL (≤25/>25) 42/50 30/61 0.096 36/58 38/56 0.881
 Child–Pugh class (A/B) 85/7 85/6 1.000 89/5 86/8 0.567
 Tumor number (single/multiple) 78/14 61/30 0.006 69/25 75/19 0.389
 Tumor size, cm (≤5/>5) 48/44 28/63 0.004 38/56 42/52 0.658
 Vascular invasion (absent/present) 87/5 85/6 0.767 88/6 89/5 1.000
 TNM stage (I/II + III) 72/20 53/38 0.004 63/31 67/27 0.636
 Histological grade (I/II/III/other) 71/21 50/41 0.002 68/26 57/37 0.122
GC patients
 Gender (male/female) 45/21 51/14 0.237 45/21 50/16 0.439
 Tumor size, cm (≤4/>4) 23/43 20/45 0.711 22/44 23/43 1.000
 Tumor depth (pT1 + pT2 pT3/pT4) 20/46 21/44 0.852 22/44 24/42 0.855
 Lymph node metastasis (pN0 + pN1/pN2 + pN3) 32/34 23/42 0.158 28/38 29/37 1.000
 TNM stage (I + II vs. III + IV) 19/47 15/50 0.551 16/50 21/45 0.439
 Histological grade (I + II/III/other) 19/42/5 14/45/4 0.637 22/37/6 13/49/4 0.112
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